Key result
Oral verapamil-SR therapy for 2 to 3 months lowered arterial pressure by 15% without causing reflex tachycardia or volume expansion, unlike intravenous verapamil.
Why the study?
Does intravenous and oral slow-release verapamil reduce arterial pressure and alter hemodynamics in patients with mild-to-moderate essential hypertension?
Observational (n=10)
Does intravenous and oral slow-release verapamil reduce arterial pressure and alter hemodynamics in patients with mild-to-moderate essential hypertension?
Oral slow-release verapamil is an effective antihypertensive that lowers blood pressure via vasodilation without the adverse reflex hemodynamic effects seen with intravenous administration.
Answers are grounded in this paper and cite their sources.
Oral verapamil-SR was associated with BP reduction without reflex effects; leaves open randomized confirmation before practice change.
The cardiovascular effects of intravenous verapamil and 3 months of oral administration of a slow-release form of verapamil (verapamil-SR) were studied in 10 patients with mild-to-moderate essential hypertension. Intravenous verapamil reduced arterial pressure by 15% (p less than .01) through a fall in total peripheral resistance of 29% (p less than .01); provoked a reflexive rise in heart rate (by 19%, p less than .02), cardiac output (by 74%, p less than .01), and plasma catecholamines; and shifted intravascular volume toward the cardiopulmonary circulation indicating peripheral venoconstriction. Quite in contrast to the immediate effects of the intravenous drug, oral therapy with verapamil-SR for 2 to 3 months lowered arterial pressure effectively (by 15%, p less than .01) by inducing vasodilation of 15% (p less than .02), but without causing reflex tachycardia, activation of the sympathetic-adrenergic or renin-angiotensin systems, or volume expansion. Oral therapy with verapamil-SR preserved systemic and renal blood flow and slightly reduced cardiac mass (by 6%, p less than .05) and renal vascular resistance (by 25%, p less than .05). Whereas intravenous verapamil tended to depress myocardial contractility, oral verapamil-SR did not at all affect myocardial contractility or left ventricular function. These cardiovascular effects make verapamil-SR an excellent agent for long-term antihypertensive therapy.
No takes yet. Share an insight, caveat, or question.
Schmieder et al. (1987) conducted an observational in mild-to-moderate essential hypertension (n=10). Intravenous verapamil and oral verapamil-SR was evaluated on Arterial pressure (p=<.01). Oral verapamil-SR therapy for 2 to 3 months lowered arterial pressure by 15% without causing reflex tachycardia or volume expansion, unlike intravenous verapamil.
Synapse has enriched 10 related papers. Consider them for comparative context: